Navigation Links
Phase I/II-data on Systemic Application of the TGF-beta2-inhibitor,AP 12009 to be Presented

REGENSBURG, Germany, May 10th, 2007 - Antisense Pharma today announced, that the abstract entitled “Preliminary Results of a Phase I/II-Study in Pancreatic Carcinoma, Malignant Melanoma, and Colorectal Carcinoma with the TGF-beta2 Inhibitor AP 12009” has been selected for poster presentation at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held in Chicago, Illinois, U.S.A, from June 1st - 5th.

In the Phase I/II-trial the antisense drug AP 12009 is administered intravenously in patients with either pancreatic carcinoma (stage IVA/IVB), metastatic melanoma (stage III/IV), or advanced colorectal carcinoma (stage III/IV) as a 7-day continuous infusion every other week. “The first milestone of the study has been achieved, as the maximum tolerated dose was determined with this treatment schedule”, explains Hubert Heinrichs, M.D., Ph.D., Chief Medical Officer at Antisense Pharma. Patient recruitment is still ongoing in study sites in Germany as further dose escalations with a modified dosing schedule are now performed. The design of the study, first efficacy and safety data will be presented at the poster presentation (Poster Board No. AA5, Abstract ID 4607) on June 4th 2007 from 8:00 a.m. to 12:00 p.m. in the session “Gastrointestinal (Noncolorectal) Cancer”. Prof. Thomas Seufferlein, Vice Head of the Department of Internal Medicine at the University of Ulm and Principal Investigator of the Phase I/II-Study will be available for questions from 11:00 a.m. to 12:00 p.m. at the poster in Hall A2 on Level 3 of McCormick Place South Building.

About Antisense Pharma

Antisense Pharma is a biopharmaceutical company located in Regensburg, Germany. The company focuses on targeted therapies for malignant tumors and is dedicated to discovering and developing drugs based on antisense technology for worldwide commercialization.

The agents specifically block the synthesis of key cancer proteins. The lead product AP 12009 is targeting Transforming Growth Factor-beta2 (TGF-beta2), a crucial factor that promotes tumor progression via multiple pathomechanisms. AP 12009 is in advanced clinical development for the treatment of high-grade glioma as well as in Phase I/II clinical trial for various other solid tumors. The further product pipeline covers preclinical drug candidates as well as compounds in research and discovery. Antisense Pharma has been honored with the Bavarian Innovation Award and the German Founders Award.

This document contains forward-looking statements with respect to the future business of Antisense Pharma GmbH. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that could occur in the future. There is a number of factors that could cause actual results and developments to differ materially. Antisense Pharma GmbH disclaims any intent of obligation to update any of these forward-looking statements.

For further information please contact:

ANTISENSE PHARMA GmbH

Dr. Heike Specht / Public Relations
Josef-Engert-Str. 9, D-93053 Regensburg
Phone: +49-941-92013-0
Fax: +49-941-92013-29
e-mail: pr@antisense-pharma.com
www.antisense-pharma.com


'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Research ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural Health ... Structural electronics involves electronic and/or electrical ... structures, replacing dumb structures such as vehicle bodies ...
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
Breaking Medicine News(10 mins):